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Abstract The tricyclic antidepressant desipramine causes a de-
crease in cellular acid sphingomyelinase (A-SMase, EC
3.1.4.12) activity when added to culture medium of human ¢bro-
blasts. This e¡ect can be prevented by incubation of the cells with
the protease inhibitor leupeptin, which suggests that desipramine
induces proteolytic degradation of the lysosomal enzyme. By
using surface plasmon resonance (SPR, Biacore) we were able
to monitor the interactions of A-SMase and substrate-contain-
ing lipid bilayers immobilized on the surface of a Pioneer1 L1
sensor chip. SPR binding curves show that the enzyme hardly
dissociates from the lipid surface at acidic pH values. On the
other hand, a drop in binding signals (resonance units, RU) of
approximately 50% occurred after injection of 20 mM desipra-
mine. Our ¢ndings indicate that desipramine interferes with the
binding of A-SMase to the lipid bilayers and thereby displaces
the enzyme from its membrane-bound substrate. The application
of control substances suggests a key role for the cationic moiety
of desipramine. We hypothesize that the displacement of the
glycoprotein A-SMase from the inner membranes of late endo-
somes and lysosomes by desipramine renders it susceptible to
proteolytic cleavage by lysosomal proteases.
6 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Acid sphingomyelinase (A-SMase, EC 3.1.4.12) is a lyso-
somal hydrolase that catalyzes the degradation of sphingo-
myelin (SM) to phosphorylcholine and ceramide. Inherited
de¢ciencies of A-SMase activity lead to di¡erent forms of
Niemann^Pick disease, which are characterized by lysosomal
SM accumulation [1].
Membrane constituents of eukaryotic cells like SM, a phos-
pholipid mainly located in the exolea£et of the plasma mem-
brane, are internalized by endocytotic processes and degraded
within the acidic organelles. During transport through the
endosomal compartments, plasma membrane components
form intraendosomal and later on intralysosomal structures
and vesicles [2,3]. Inside the lysosomes, they become sub-
strates for various exohydrolases that remove sugar residues
from glycosphingolipids or, in the case of A-SMase, phos-
phorylcholine from SM.
Acidic compartments of the cell contain the phospholipid
bis(monoacylglycero)phosphate (BMP) [4^6] which was de-
tected at highest levels in internal vesicles and membranes of
lysosomes [7]. BMP was shown to remain negatively charged
even at pH 4.2 [8]. Since A-SMase has an isoelectric point of
around 6.8, it possesses positively charged regions in the
acidic lysosomal environment. These regions most likely con-
tribute to the interaction of the enzyme with the anionic mem-
brane-bound BMP. Linke et al. [9] performed surface plasmon
resonance (SPR) experiments using liposomes with varying
lipid composition and demonstrated that the binding of A-
SMase to liposomes containing BMP is enhanced by almost
50% compared to vesicles free of BMP. On the other hand,
the presence or absence of SM in the vesicles had no signi¢-
cant e¡ect [9].
In 1981, Albouz et al. [10] reported that the tricyclic anti-
depressant desipramine causes a decrease of A-SMase activity
in cultured murine neuroblastoma cells and human ¢bro-
blasts. Lysosomal inclusions similar to those known from pa-
tients with lipid storage diseases were observed in various
organs of rats upon treatment with amphiphilic cationic
drugs, including lung and liver as well as the central nervous
system. Retinal alterations, corneal opacities, hepatospleno-
megaly, abnormalities of liver function and neuro-myopathies
accompanied by inclusions especially abundant in Schwann
cells were observed in humans [11^14].
Added at a concentration of 25 WM to the cell culture
medium, desipramine gave rise to a reduction of A-SMase
activity down to 20% of controls within 2 h [15]. A direct
inhibition of the enzyme by cationic amphiphilic drugs and
a diminished biosynthesis of A-SMase were ruled out to be
responsible for this e¡ect, as well as an association of SMase
activity with the desipramine-induced downregulation of
L-adrenoceptors [16,17]. Hurwitz et al. [15] showed that treat-
ment with desipramine leads to intracellular degradation of
the mature enzyme which can be prevented by preincubation
of the cells with the protease inhibitor leupeptin. To provide
new insight into the interactions of A-SMase and lipid bi-
layers in the presence of desipramine we here present the
results of our studies using SPR (Biacore).
2. Materials and methods
2.1. Materials
SM, phosphatidylcholine and cholesterol, 1,7-diaminoheptane,
1,2,3-heptanetriol, hexanoic acid and desipramine were obtained
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from Sigma (Taufkirchen, Germany) and BMP (dioleoyl) from Avanti
Polar Lipids, Inc. (Alabaster, AL, USA).
2.2. Expression and puri¢cation of human A-SMase (hA-SMase)
The authors thank Stephanie Lansmann (Bonn, Germany) for pro-
viding puri¢ed hA-SMase. hA-SMase was expressed using the bacu-
lovirus expression vector system [18] and puri¢ed from insect Sf21
cells to homogeneity as described by Lansmann et al. [19]. The re-
combinant enzyme had a speci¢c activity of 0.8 mmol/h/mg puri¢ed in
the presence of Zn2þ (0.1 mM) and measured in a micellar assay
system.
2.3. Preparation of liposomes
Preparation of large unilamellar liposomes (LUVs) has been de-
scribed previously [9,20]. Brie£y, a lipid mixture consisting of 10
mol% SM, 50 mol% phosphatidylcholine, 20 mol% cholesterol and
20 mol% BMP (for neutral liposomes: 10 mol% SM, 70 mol% phos-
phatidylcholine, 20 mol% cholesterol), dissolved in organic solvents,
was dried under a stream of nitrogen and then rehydrated in phos-
phate-bu¡ered saline bu¡er, pH 7.4 (loading bu¡er). The mixture was
freeze-thawed six times in liquid nitrogen and in an incubator at 37‡C,
respectively, and passed 17 times through a polycarbonate membrane
with a pore diameter of 100 nm.
2.4. SPR (Biacore)
SPR measurements were performed using a Biacore 3000 system at
25‡C. LUVs (total lipid concentration 0.1 mM) were immobilized on
the surface of a Pioneer1 L1 sensor chip (Biacore) in loading bu¡er.
The running bu¡er used was 50 mM sodium acetate bu¡er, pH 4.5 or
a 50 mM sodium acetate solution, pH 7.4 in control experiments.
A-SMase (0.2 WM, 70 Wl) was injected in running bu¡er at a £ow
rate of 20 Wl/min. 1,7-Diaminoheptane, 1,2,3-heptanetriol, hexanoic
acid and desipramine (60 Wl, dissolved in water) were injected for
180 s (£ow rate 20 Wl/min) in the concentrations indicated in the
¢gures.
3. Results and discussion
In order to monitor the binding of A-SMase to substrate-
containing membranes, we immobilized liposomes composed
of 10 mol% SM, 20 mol% BMP, 20 mol% cholesterol and 50
mol% phosphatidylcholine on the surface of a Pioneer1 L1
sensor chip. The enzyme was injected in sodium acetate bu¡-
er, pH 4.5. As observed before [9], the enzyme binds and
hardly dissociates from the lipid surface when the £ow is
switched to sodium acetate bu¡er devoid of A-SMase.
Cationic amphiphilic drugs such as desipramine strongly
accumulate inside the acidic compartments of living cells since
they become trapped as membrane-impermeable forms subse-
quent to their protonation in the acidic environment. This
e¡ect should especially be considered with patients who take
desipramine for a long period of time. It is known that the
lysosomal concentration of cationic amphiphilic drugs can
reach millimolar levels. Hostetler et al. [21] measured 6.3
mM chloroquine in lysosomes isolated from the liver of rats
treated with 100 mg/kg/day of the drug at 12 h and 74 mM at
72 h.
To simulate that situation, we injected 20 mM desipramine
in our Biacore system, which caused a drop in binding signals
(resonance units, RU) of approximately 50%. At a concentra-
tion of 50 mM desipramine, the enzyme was completely re-
leased from its membrane-bound substrate without removing
the lipid vesicles (Fig. 1). These ¢ndings suggest that the cat-
ionic amphiphile desipramine interferes with the binding of A-
SMase to the anionic liposomes at acidic pH values and there-
by displaces the enzyme from its substrate.
As a control, we replaced desipramine with a di¡erent cat-
ionic, a neutral and an anionic compound. 1,7-Diaminohep-
tane, a substance that is devoid of the tricyclic aromatic core
of desipramine but carries two positively charged groups, ef-
fectively displaces A-SMase from the lipid surface at pH 4.5
(Fig. 2). Injection of the neutral 1,2,3-heptanetriol and the
Fig. 1. Interaction of A-SMase with immobilized anionic liposomes
in the presence of desipramine at pH 4.5. LUVs (average diameter
100 nm, total lipid concentration 0.1 mM) were immobilized on a
Pioneer1 L1 sensor chip. The vesicles were composed of 50 mol%
phosphatidylcholine, 20 mol% cholesterol, 20 mol% BMP and 10
mol% SM. Response signals measured subsequent to the binding of
the liposomes were de¢ned as zero. A-SMase (0.2 WM), desipramine
or running bu¡er (50 mM sodium acetate bu¡er, pH 4.5) were in-
jected as indicated.
Fig. 2. In£uence of control substances on the binding of A-SMase
to immobilized anionic liposomes at pH 4.5. After immobilization
of LUVs and A-SMase as described under Fig. 1, hexanoic acid,
1,2,3-heptanetriol and 1,7-diaminoheptane, respectively, were in-
jected at the concentrations indicated. Response signals measured
subsequent to the binding of A-SMase to the liposomal surface
were de¢ned as zero.
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partially anionic hexanoic acid did not lead to a release of the
enzyme from the liposomes at acidic pH values (Fig. 2). Since
1,2,3-heptanetriol and hexanoic acid are amphiphilic mole-
cules like desipramine, these data prove that the amphiphilic
character of a substance is not su⁄cient to a¡ect the binding
of A-SMase to the lipid vesicles.
Our results support the assumption that the cationic groups
of the amphiphile desipramine contribute to the decreased
binding of the enzyme to its membrane-bound lipid substrate,
presumably by competing with the interactions of the at acidic
pH values cationic A-SMase with the anionic BMP in the
membranes.
50 mM desipramine neither interfered speci¢cally with the
binding of A-SMase to BMP-containing liposomes at pH 7.4
nor when neutral liposomes without BMP were used at pH
4.5. In both cases, however, desipramine acted like an unspe-
ci¢c detergent resulting in e¡ects similar to those of the neu-
tral detergent CHAPS (3-[(3-cholamidopropyl)dimethylam-
monio]-1-propanesulfonate), for instance. Response signals
returned to the level measured for the Pioneer1 L1 sensor
chip alone which indicates that lipids and protein together
were completely washed o¡ the sensor chip (data not shown).
Thus, in accordance with our hypothesis, the cationic form of
desipramine as well as anionic lipid bilayers interacting with a
cationic A-SMase are crucial to cause the release of the en-
zyme from the liposomes.
A-SMase is a glycoprotein with six potential N-glycosyla-
tion sites, ¢ve of which were shown to be used by expression
of mutated hA-SMase cDNA constructs in COS cells [22] ; all
glycosylation sites of recombinant hA-SMase puri¢ed from
insect cells are used [23].
These complex oligosaccharide chains possibly protect the
membrane-associated enzyme from proteolytic cleavage in the
lysosome. However, once released from the substrate-bearing
membranes, A-SMase may expose di¡erent sites to the lyso-
somal proteases and thus become susceptible for proteolytic
degradation. As demonstrated before, treatment of cultured
¢broblasts with desipramine leads to intracellular degradation
of mature A-SMase which can be prevented by incubation of
the cells with the protease inhibitor leupeptin [15]. Our results
suggest that desipramine possibly induces intracellular pro-
teolysis of A-SMase by displacing the enzyme from its mem-
brane-bound lipid substrate and thereby making it sensitive to
proteolysis. The resulting loss of lysosomal A-SMase activity
may well trigger the lysosomal lipid accumulation described
before [10^14].
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